3'-氨基联苯-4-羧酸甲酯 | 159503-24-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3'-氨基联苯-4-羧酸甲酯
• 中文别名: 4'-氨基-联苯基-3-羧酸甲酯
• 英文名称: methyl 3'-amino-[1,1'-biphenyl]-4-carboxylate
• 英文别名: methyl 3’-amino-[1,1’-biphenyl]-4-carboxylate；3'-Amino-biphenyl-4-carboxylic acid methyl ester；Methyl 4-(3-aminophenyl)benzoate
• CAS: 159503-24-9
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: VXTVRZIUOJSIIN-UHFFFAOYSA-N

物化性质

• 沸点：
  411.8±38.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2922499990
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-(3-aminophenyl)benzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-(3-aminophenyl)benzoate
CAS number: 159503-24-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H13NO2
Molecular weight: 227.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3'-氨基联苯-4-羧酸甲酯 在 吡啶 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 aq. phosphate buffer 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 150.08h， 生成 4-(2-methoxy-4-(1-((3'-(methylsulfonamido)-[1,1'-biphenyl]-4-carboxamido)oxy)ethyl)-5-nitrophenoxy)butanoic acid
  参考文献：
  名称：

  新型光活化组蛋白脱乙酰基酶抑制剂的合成和生物学评估。

  摘要：

  基于异羟肟酸的组蛋白脱乙酰基酶抑制剂（HDACi）是一类表观遗传药物，对包括血管成形术后介导的新内膜增生（NIH）在内的几种疾病都有潜在的广泛治疗应用。为了在NIH药物洗脱球囊导管（DEBc）血管成形术治疗中安全且成功地使用HDACi，需要对目标血管部位HDACi的释放进行精确的时空控制。我们旨在开发和表征新型光敏性HDACi（metacept-3 1），作为DEBc的潜在涂层剂。 Metacept-3 1被笼罩着对光不稳定的保护基（PPG），以合成新型UV365nm活性HDACi，笼养的metacept-3 15。笼metacept-3的转化率15到有源/天然metacept-3 1通过UV365nm在显著数量和在毫瓦（MW）范围UV365nm功率电平实现的。 对笼中的metacept-3 15进行UV365nm活化前后的生物学活性的体外评估发现，暴露于短时间，mW范围的UV365nm的

  DOI：

  10.1016/j.bmcl.2020.127291
• 作为产物：
  描述：

  3-硝基苯硼酸 在 palladium 10% on activated carbon 、 氢气 、 sodium carbonate 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 52.0h， 生成 3'-氨基联苯-4-羧酸甲酯
  参考文献：
  名称：

  新型光活化组蛋白脱乙酰基酶抑制剂的合成和生物学评估。

  摘要：

  基于异羟肟酸的组蛋白脱乙酰基酶抑制剂（HDACi）是一类表观遗传药物，对包括血管成形术后介导的新内膜增生（NIH）在内的几种疾病都有潜在的广泛治疗应用。为了在NIH药物洗脱球囊导管（DEBc）血管成形术治疗中安全且成功地使用HDACi，需要对目标血管部位HDACi的释放进行精确的时空控制。我们旨在开发和表征新型光敏性HDACi（metacept-3 1），作为DEBc的潜在涂层剂。 Metacept-3 1被笼罩着对光不稳定的保护基（PPG），以合成新型UV365nm活性HDACi，笼养的metacept-3 15。笼metacept-3的转化率15到有源/天然metacept-3 1通过UV365nm在显著数量和在毫瓦（MW）范围UV365nm功率电平实现的。 对笼中的metacept-3 15进行UV365nm活化前后的生物学活性的体外评估发现，暴露于短时间，mW范围的UV365nm的

  DOI：

  10.1016/j.bmcl.2020.127291

文献信息

• [EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2015138895A1

  公开（公告）日：2015-09-17

  ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

  摘要 本公开提供了部分具有对乙型肝炎病毒Cp具有变构效应的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向需要的患者施用所述化合物。
• Thiazolopyrimidine derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05599813A1

  公开（公告）日：1997-02-04

  Thiazolopyrimidine derivatives represented by the formula ##STR1## and salts thereof are provided, which are characterized by a carboxamide residue substituted with R.sup.4 and R.sup.5. The derivatives and salts thereof exhibit antiangiogenic activity and are useful for treatment and cure of diseases, the development of which may be related to angiogenesis, including diabetic retinopathy, various chronic inflammation conditions, growth or metastasis of malignant solid tumors, rheumatism and psoriasis.

  提供了由公式##STR1##表示的噻唑吡咯啉衍生物及其盐，其特征在于带有R.sup.4和R.sup.5取代的羧酰胺残基。这些衍生物及其盐表现出抗血管生成活性，并可用于治疗和治愈可能与血管生成有关的疾病，包括糖尿病视网膜病变、各种慢性炎症症状、恶性实体肿瘤的生长或转移、风湿病和牛皮癣。
• SUBSTITUTED TRICYCLICS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170015675A1

  公开（公告）日：2017-01-19

  The present invention provides for compounds of formula (I) wherein X, Y, and R 1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中X、Y和R1具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• [EN] 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS<br/>[FR] SELS DE 1,3,4-BENZOTRIAZEPINE ET LEUR UTILISATION COMME LIGANDS DU RECEPTEUR DE CCK
  申请人：JOHNSON & JOHNSON

  公开号：WO2004101533A1

  公开（公告）日：2004-11-25

  This invention relates to pharmaceutically acceptable salts of compounds of formula (I) wherein: W is N or N+-O-; R2 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms. R3 is -(CR11R12)m-X-(CR13R14)p-R9; m is 0, 1, 2, 3 or 4; p is 0, 1 or 2; X is a bond, -CR15=CR16-, -C≡C-, C(O)NH, NHC(O), C(O)NMe, NMeC(O), C(O)O, NHC(O)NH, NHC(O)O, OC(O)NH, NH, O, CO, SO2, SO2NH, C(O)NHNH, R9 is H ; C1 to C6 alkyl ; or phenyl, naphthyl, pyridyl, benzimidazolyl, indazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolinyl, isoindolinyl, indolyl, isoindolyl or 2-pyridonyl substituted with -L-Q. R4 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms ; and Such salts are useful, for example, for the treatment of gastrin related disorders.

  该发明涉及公式（I）化合物的药用可接受盐，其中：W为N或N+-O-；R2为可选择取代的C1至C18烃基团，其中最多三个C原子可选择地被N、O和/或S原子取代。R3为-(CR11R12)m-X-(CR13R14)p-R9；m为0、1、2、3或4；p为0、1或2；X为键、-CR15=CR16-、-C≡C-、C(O)NH、NHC(O)、C(O)NMe、NMeC(O)、C(O)O、NHC(O)NH、NHC(O)O、OC(O)NH、NH、O、CO、SO2、SO2NH、C(O)NHNH；R9为H、C1至C6烷基或苯基、萘基、吡啶基、苯并咪唑基、吲哚基、喹啉基、异喹啉基、四氢异喹啉基、吲哚啉基、异吲哚啉基、吲哚基、异吲哚基或2-吡啶酰基，取代为-L-Q。R4为可选择取代的C1至C18烃基团，其中最多三个C原子可选择地被N、O和/或S原子取代；这些盐可用于治疗胃泌素相关疾病。
• [EN] METHOD OF TREATMENT AND DEVICE<br/>[FR] MÉTHODE DE TRAITEMENT ET DISPOSITIF
  申请人：UNIV MONASH

  公开号：WO2020142809A1

  公开（公告）日：2020-07-16

  A method and an angioplasty balloon catheter used in a method of preventing or minimizing incidence of neointimal hyperplasia (NIH) in a blood vessel of an animal following angioplasty treatment. The method comprising locating the angioplasty balloon catheter at a vessel site where angioplasty treatment is desired, wherein a balloon component of the catheter is at least partially coated on an external surface thereof with a photo-labile drug / linker conjugate of Formula I; wherein the balloon is inflated at the site to initiate release of the drug / linker conjugate to vessel wall at the site and an optical fiber light diffuser, connected by optical fiber to a source of UV light at a wavelength of from about 350 nm to about 380 nm, is located within the balloon to emit said UV light, wherein UV light emission is of suitable power and for sufficient duration to cleave the drug / linker conjugate and activate an effective amount of the drug of Formula II to prevent or minimize NIH following the angioplasty treatment at the site.

  本发明涉及一种方法和一种用于预防或最小化在动物的血管内进行成形术治疗后发生新内膜增生（NIH）的血管成形术球囊导管。该方法包括将血管成形术球囊导管定位在需要进行血管成形术治疗的血管部位，其中导管的球囊组件至少部分地涂覆有配方I的光敏药物/连接剂共轭物的外表面；在该部位充气球囊以启动在该部位向血管壁释放药物/连接剂共轭物，并且在球囊内放置光纤光扩散器，通过光纤连接到波长为约350nm至约380nm的紫外线光源，其中紫外线光发射具有足够的功率和足够长的持续时间，以断裂药物/连接剂共轭物并激活配方II的有效量，以预防或最小化在该部位进行血管成形术治疗后的NIH。